|
|
Article: Genome Therapeutics Receives Patent for Genetic Sequences of Enterococcus faecium, Most Common Species of Vancomycin-Resistant Enterococci.
- Article from:
- Business Wire
- Article date:
- July 23, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
WALTHAM, Mass.--(BUSINESS WIRE)--July 23, 2003
Three new patents support intellectual property portfolio of
Company's infectious diseases program
The U.S. Patent and Trademark Office has issued U.S. Patent No. 6,583,275 to Genome Therapeutics (Nasdaq: GENE) relating to the pathogen Enterococcus faecium (E. faecium). The most common species of enterococcus that develops resistance to antibiotics such as vancomycin, E. faecium can cause deadly bloodstream infections in hospitalized patients. The patent relates to key genetic sequences that have the potential to aid in the identification and ...